创胜集团
TRANSCENTA

Transcenta Holding Limited
創勝集團醫藥有限公司
(registered by way of continuation in the Cayman Islands with limited liability)
(Stock Code: 6628)

CLARIFICATION AND SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE GRANT OF OPTIONS PURSUANT TO THE SHARE INCENTIVE SCHEME IN JUNE 2025

Reference is made to the announcement of Transcenta Holding Limited (the "**Company**", and together with its subsidiaries, the "**Group**") dated June 25, 2025 in relation to, among others, the grant of 2,000,000 options to one (1) Option Grantee under the Share Incentive Scheme of the Company (the "**Announcement**"). Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

SUPPLEMENTAL INFORMATION

The Company would like to provide the following supplemental information:

The Option Grantee of the June Option Grant is Dr. Caroline Germa ("**Dr. Germa**"), M.D., Ph.D., who previously served as the Executive Vice President, Global Medicine Development and Chief Medical Officer of the Company. Presently, Dr. Germa is engaged as a consultant of the Company by an advisory agreement therewith, pursuant to which she has continued to contribute to the Company's long-term development in her capacity as a member of the Company's science advisory board for a term of three years.

Dr. Germa provides continuous advisory services to the Company on a continuing basis, including but not limited to advising the Company on clinical development strategy, interactions with multiple regulatory agencies, fund raising, business development efforts and scientific direction of the Group's pipeline products. These services are integral to the Group's core operations in drug discovery and development and fall within the ordinary and usual course of its business as a clinical-stage biopharmaceutical company. The Company considered Dr. Germa's continuing support essential to its operations and project implementation and her advice and industry experience will help the Company advance its pipeline going forward.

Dr. Germa is presently engaged as a consultant of the Company on a continuing basis. As service providers of the Company, under the Share Incentive Scheme, may include, *inter alia*, consultants such as academics, industry experts and professionals with distinguished backgrounds in scientific research and expertise in biopharmaceutical research, logistics and manufacturing industry who, due to various reasons, may not be able to serve as full-time or part-time employees, directors or officers of the Group but nonetheless provide significant contributions to the growth of the Group's financial or business performance through continuing or discrete projects. Dr. Germa who meets the foregoing criteria thus qualifies as a service provider of the Company based on the significance of her role and the materiality of her contributions towards attaining the relevant project milestones.

The June Option Grant to Dr. Germa is intended to incentivize and retain her continued engagement with the Group, to motivate her to close in on clinical development milestones, and to align her interests with those of the Company and its Shareholders, in line with industry practices and the purposes of the Share Incentive Scheme. The vesting of the June Option Grant is subject to the achievement of performance targets relating to milestones in clinical development and business development, which are consistent with the Group's strategic goals.

CLARIFICATION

The Company wishes to clarify that vesting of the June Option Grant to Dr. Germa is subject to a performance-based vesting schedule (in lieu of time-based vesting criteria), and that due to the unpredictability inherent in clinical development, one or more of the milestones stipulated in the option letter may be achieved within 12 months from the date of grant. In any cases, the corresponding Options shall be "unlocked", and become exercisable upon the commencement of the exercise period, which shall fall on a date which is not less than 12 months from the date of grant in accordance with the Listing Rules.

The above supplemental information and the clarification in this announcement do not affect other information contained in the Announcement and, save as disclosed in this announcement, the contents of the Announcement remains unchanged.

By Order of the Board
Transcenta Holding Limited
Xueming Qian
Executive Director, Chairman and
Chief Executive Officer

Hong Kong, July 7, 2025

As at the date of this announcement, the board of directors of the Company comprises Dr. Xueming Qian as executive Director, chairman and chief executive officer, Dr. Li Xu as non-executive Director and Mr. Jiasong Tang, Mr. Zhihua Zhang, Dr. Kumar Srinivasan and Ms. Helen Wei Chen as independent non-executive Directors.